We are a leader in the development and sale of innovative, broadly enabling, pressure-based platform solutions for the worldwide life sciences industry. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology platform) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be acceptably preserved using existing non-thermal technologies.

Company profile
Ticker
PBIO
Exchange
Website
CEO
Richard T. Schumacher
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Agilent • Perkinelmer • Bio-Rad Laboratories • Waters • Avantor • Illumina • Mettler-Toledo International • Bruker • Coherent • Seer ...
Former names
BOSTON BIOMEDICA INC
SEC CIK
Corporate docs
Subsidiaries
PBI Agrochem, Inc. • PBI BioSeq, Inc. • Pressure BioSciences Europe ...
IRS number
42652826
PBIO stock data
Press releases
Pressure BioSciences Announces Contract for October 2022 Launch of Breakthrough Hemp-Derived CBD Product, Estimating $2 Million Incremental 2023 Revenue
18 Aug 22
Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update
16 Aug 22
Pressure BioSciences Announces Approval to Manufacture Hemp-Derived CBD Products in Massachusetts, Including Their Revolutionary CBD Nanoemulsions
11 Aug 22
Pressure BioSciences Doubles Growth Projections for UST Nanoemulsion Contracts Following Clear Confirmation of Unmet Needs in Exploding Cannabis Drinks Sector
5 Aug 22
Pressure BioSciences Announces Second Contract for Toll Manufacturing of a CBD Nanoemulsion Product Using Its Proprietary Ultra Shear Technology Platform
21 Jul 22
Investment data
Securities sold
Number of investors
Calendar
15 Aug 22
18 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 121.57K | 121.57K | 121.57K | 121.57K | 121.57K | 121.57K |
Cash burn (monthly) | (no burn) | (no burn) | 300.54K | 370.97K | 413.97K | 398K |
Cash used (since last report) | n/a | n/a | 494.97K | 610.95K | 681.77K | 655.47K |
Cash remaining | n/a | n/a | -373.4K | -489.38K | -560.2K | -533.91K |
Runway (months of cash) | n/a | n/a | -1.2 | -1.3 | -1.4 | -1.3 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jul 22 | Schumacher Richard T | Common Stock | Other | Acquire J | No | No | 1.69 | 952 | 1.61K | 40,729 |
29 Jul 22 | Alexander V Lazarev | Common Stock | Other | Acquire J | No | No | 1.69 | 784 | 1.32K | 2,577 |
29 Jul 22 | Mangiardi Vito J | Common Stock | Other | Acquire J | No | No | 1.69 | 131 | 221.39 | 13,447 |
29 Jul 22 | Pollack Kevin | Common Stock | Other | Acquire J | No | No | 1.69 | 609 | 1.03K | 24,401 |
29 Jul 22 | Peterson Jeffrey N | Common Stock | Other | Acquire J | No | No | 1.69 | 2,481 | 4.19K | 31,962 |
Institutional ownership, Q1 2022
4.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 11.87M |
Total shares | 421.02K |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LG Capital Funding | 415.01K | $950K |
Archer Investment | 6K | $10.92M |
Eagle Equities | 10 | $0 |
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
clear, Coast, confirmation, doubling, engineering, expended, exploding, headcount, illuminate, launch, Midwest, offered, oral, predominantly, proprietary, reputation, revolutionize, role, secondarily, shifted, spray, toll, unmet, weekly
Removed:
bioavailability, biotherapeutic, care, controlled, focusing, gently, greatly, historically, industrial, leader, personal, reach, sensory, settlement, spanning
Current reports
8-K
Submission of Matters to a Vote of Security Holders
4 Jan 22
8-K
Regulation FD Disclosure
20 Aug 21
8-K
Entry into a Material Definitive Agreement
31 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
9 Dec 20
8-K
Entry into a Material Definitive Agreement
6 Nov 20
8-K
Entry into a Material Definitive Agreement
9 Oct 20
8-K
Entry into a Material Definitive Agreement
8 Jul 20
8-K
Other Events
15 May 20
8-K
Entry into a Material Definitive Agreement
6 Mar 20
8-K
Entry into a Material Definitive Agreement
5 Feb 20
Registration and prospectus
D
Indefinite amount in equity / options / securities to be acquired, sold $17.46M, 43 investors
20 Mar 19
RW
Registration withdrawal request
14 Aug 17
8-A12B
Registration of securities on exchange
9 Aug 17
S-1/A
IPO registration (amended)
10 Apr 17
S-1
IPO registration
21 Dec 16
D
$6.25M in equity / options / securities to be acquired, sold $5.01M, 22 investors
26 Jan 16
Other
EFFECT
Notice of effectiveness
25 Sep 11
UPLOAD
Letter from SEC
21 Dec 09
CORRESP
Correspondence with SEC
2 Dec 09
UPLOAD
Letter from SEC
1 Dec 09
CORRESP
Correspondence with SEC
16 Nov 09
UPLOAD
Letter from SEC
4 Nov 09
UPLOAD
Letter from SEC
21 Aug 08
CORRESP
Correspondence with SEC
20 Aug 08
CORRESP
Correspondence with SEC
20 Aug 08
UPLOAD
Letter from SEC
19 Aug 08
Ownership
4
PRESSURE BIOSCIENCES / Michael S Urdea ownership change
2 Aug 22
4
PRESSURE BIOSCIENCES / Kevin Pollack ownership change
2 Aug 22
4
PRESSURE BIOSCIENCES / JEFFREY N PETERSON ownership change
2 Aug 22
4
PRESSURE BIOSCIENCES / Vito J Mangiardi ownership change
2 Aug 22
4
PRESSURE BIOSCIENCES / Alexander V Lazarev ownership change
2 Aug 22
4
PRESSURE BIOSCIENCES / RICHARD T SCHUMACHER ownership change
2 Aug 22
4
PRESSURE BIOSCIENCES / Alexander V Lazarev ownership change
28 Jun 22
4
PRESSURE BIOSCIENCES / Vito J Mangiardi ownership change
28 Jun 22
4
PRESSURE BIOSCIENCES / Michael S Urdea ownership change
28 Jun 22
4
PRESSURE BIOSCIENCES / RICHARD T SCHUMACHER ownership change
28 Jun 22
Patents
Utility
Ultrahigh pressure compact valve with throttling capability
26 Oct 21
A high pressure valve includes a lever and a variable force generator for facilitating control of opening and closing the valve at high pressures.
Utility
System for high pressure, high shear processing of fluids
2 Nov 20
A method for high fluid shear processing of a fluid uses an isolator that has a first sub-chamber for containing a first fluid and a second sub-chamber for containing a second fluid defined by a separator positioned in the chamber and movable between a first end of the chamber and a second end of the chamber.
Utility
Sample preparation devices and methods
13 Jul 20
Devices and methods for sample preparation via pressure cycling technology are disclosed.
Reddit threads
Pressure BioSciences, Inc. (OTCQB: $PBIO)
16 Aug 22
Analysis of: (OTCQB: $PBIO) Pressure BioSciences, Inc.
16 Aug 22
(OTCQB: $PBIO)Pressure BioSciences, Inc.
13 Jul 22
Overview Analysis of Pressure BioSciences, Inc. (OTCQB: $PBIO)
21 Jun 22
Overview Analysis of Pressure BioSciences, Inc. (OTCQB: $PBIO)
7 Jun 22
I want to talk about the PBIO UST platform some more because it’s the one that��s hot right now and is generating inquiries from many interested companies.
1 Nov 21
Milk with a 6 month shelf life? Growing Revenues, Amazing Proprietary Tech, Tiny Float 6.27M Shares. Must read report $PBIO 1000% upside
1 Nov 21
Milk with a 6 month shelf life? Growing Revenues, Amazing Proprietary Tech, Tiny Float 6.27M Shares. Must read report $PBIO
1 Nov 21
Growing Revenues, Amazing Proprietary Tech, Tiny Float 6.27M Shares and Chart Look. Must read report $PBIO
1 Nov 21
Growing Revenues, Amazing Proprietary Tech, Tiny Float 6.27M Shares and chart setup. Must read report $PBIO
1 Nov 21